vTv Therapeutics' Upcoming Investor Conference Engagements
vTv Therapeutics Inc. (NASDAQ: VTVT), a dynamic biopharmaceutical company, is set to engage with investors at significant conferences this September. The company, which focuses on pioneering therapies for managing diabetes, will participate in several targeted discussions designed to highlight its innovative approach to treatment.
Overview of vTv Therapeutics
At the heart of vTv's mission lies a commitment to developing next-generation medications aimed at alleviating the burden of diabetes and other chronic conditions. Their leading candidate, cadisegliatin, is currently advancing through a Phase 3 clinical trial. This potential first-in-class oral glucokinase activator aims to serve as an adjunctive therapy to insulin for patients battling type 1 diabetes. vTv is dedicated to bringing much-needed relief and improved options to those living with these diseases.
Scheduled Conferences for September
Management will attend two prestigious conferences, providing stellar opportunities for investors to learn more about the company’s promising future. The details of the events are outlined as follows:
H.C. Wainwright 27th Annual Global Investment Conference
This crucial event is set to occur on Tuesday, September 9. The format will consist of 1x1 investor meetings, allowing for personalized discussions regarding vTv's advancements and strategic vision.
Morgan Stanley 23rd Annual Global Healthcare Conference
On Wednesday, September 10, vTv will participate in a fireside chat scheduled for 2:35 PM to 3:10 PM EST. This session will provide an engaging platform for management to share insights and foster connections through additional 1x1 investor meetings.
Expanding Horizons in Diabetes Treatment
As the global diabetes epidemic continues to escalate, companies like vTv Therapeutics are vital in developing innovative therapies. Their research pipeline not only targets type 1 diabetes but also includes investigational drugs for various chronic diseases, aiming for significant breakthroughs in treatment paradigms. With a focus on developing small molecule drug candidates, vTv is paving the way for advancements that could transform lives.
Stay Connected with vTv Therapeutics
For those interested in more information, vTv Therapeutics encourages stakeholders to visit their website. Engaging with the company via social media platforms allows for updates on research progress and conference recaps, ensuring that followers remain informed about ongoing developments and strategic initiatives.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
Frequently Asked Questions
What is vTv Therapeutics' main focus?
vTv Therapeutics specializes in developing novel therapies for diabetes and other chronic diseases.
What is cadisegliatin?
Cadisegliatin is a potential first-in-class oral therapy aimed at enhancing treatment for type 1 diabetes patients.
When are the investor conferences happening?
The investor conferences are scheduled for September 9 and September 10.
How can I stay updated on vTv Therapeutics?
You can connect with them through their official website and social media channels for the latest news and updates.
Who can I contact for investor inquiries?
For inquiries, you can reach out to John Fraunces at LifeSci Advisors using the provided email address.
